 |
30 Diseases |  |
1 Trial |
|
1 Trial |  |
338 News |  |
| «1234 |
- | Zontivity (vorapaxar) / Merck (MSD)
Journal: Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. (Pubmed Central) - Sep 8, 2017
In patients with a prior CABG, vorapaxar significantly reduced the risk of recurrent major cardiovascular events. In patients undergoing CABG while receiving vorapaxar, bleeding risk appeared similar to that seen in the overall trial population.
- ||| Zontivity (vorapaxar) / Merck (MSD)
Trial initiation date: Vorapaxar and Lower Extremity Bypass Grafts (clinicaltrials.gov) - Aug 4, 2017
P4, N=100, Not yet recruiting, Sponsor: Vanderbilt University
In patients undergoing CABG while receiving vorapaxar, bleeding risk appeared similar to that seen in the overall trial population. Initiation date: Dec 2016 --> Aug 2017
- | Zontivity (vorapaxar) / Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date: Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access (clinicaltrials.gov) - Jul 26, 2017
P2, N=17, Active, not recruiting, Sponsor: Matthew Mell
Initiation date: Dec 2016 --> Aug 2017 Not yet recruiting --> Active, not recruiting | N=128 --> 17 | Trial primary completion date: Feb 2017 --> Oct 2017
- || Zontivity (vorapaxar) / Merck (MSD)
Trial primary completion date: ADVICE: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (clinicaltrials.gov) - Jun 22, 2017
P1/2, N=60, Recruiting, Sponsor: Kirby Institute
Not yet recruiting --> Active, not recruiting | N=128 --> 17 | Trial primary completion date: Feb 2017 --> Oct 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- | Zontivity (vorapaxar) / Merck (MSD), clopidogrel / Generic mfg.
Journal: Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. (Pubmed Central) - Jun 8, 2017
P3
Our results support adoption of the BARC bleeding scale in ACS clinical trials. (Trial to Assess the Effects of Vorapaxar [SCH 530348; MK-5348] in Preventing Heart Attack and Stroke in Participants With Acute Coronary Syndrome [TRACER] [Study P04736]; NCT00527943).
- | Zontivity (vorapaxar) / Merck (MSD)
Journal: High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. (Pubmed Central) - Jun 8, 2017
In stable patients with established atherosclerosis, hs-TnI concentrations effectively stratified the risk of new or recurrent cardiovascular (CV) events, in particular CV death and MI. High-risk patients with prior MI identified by increased hs-TnI had a substantial absolute improvement in net clinical outcome with vorapaxar.
- | Zontivity (vorapaxar) / Merck (MSD)
Journal: Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. (Pubmed Central) - May 27, 2017
High-risk patients with prior MI identified by increased hs-TnI had a substantial absolute improvement in net clinical outcome with vorapaxar. Older patients had a greater risk for ischemic and bleeding events; however, the efficacy and safety of vorapaxar in NSTE ACS were not significantly influenced by age.
- | Zontivity (vorapaxar) / Merck (MSD)
Journal: Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition. (Pubmed Central) - Apr 2, 2017
We will focus on identifying the key patient populations that should be identified for treatment, highlight practical clinical issues when prescribing vorapaxar, and review unanswered questions. Vorapaxar should be considered in patients at high risk for recurrent ischemic events and low risk of bleeding.
- | Zontivity (vorapaxar) / Merck (MSD)
Trial completion: Vorapaxar in the Human Endotoxemia Model (clinicaltrials.gov) - Mar 28, 2017
P4, N=16, Completed, Sponsor: Medical University of Vienna
Vorapaxar should be considered in patients at high risk for recurrent ischemic events and low risk of bleeding. Recruiting --> Completed
- | Zontivity (vorapaxar) / Merck (MSD)
Journal: Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. (Pubmed Central) - Mar 24, 2017
Transradial access was associated with lower bleeding rates and similar long-term ischemic outcomes, suggesting transradial access is safer than transfemoral access among ACS patients receiving potent antiplatelet therapies. Because of the nonrandomized allocation of arterial access, these results should be considered exploratory.
- || Zontivity (vorapaxar) / Merck (MSD)
Trial primary completion date: OPTIMUS-5: Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus (clinicaltrials.gov) - Mar 17, 2017
P4, N=64, Recruiting, Sponsor: University of Florida
Because of the nonrandomized allocation of arterial access, these results should be considered exploratory. Trial primary completion date: Jun 2017 --> Mar 2018
- ||||| Zontivity (vorapaxar) / Merck (MSD)
New P4 trial: Vorapaxar and Lower Extremity Bypass Grafts (clinicaltrials.gov) - Nov 29, 2016
P4, N=100, Not yet recruiting, Sponsor: Vanderbilt University
- || Zontivity (vorapaxar) / Merck (MSD)
Trial primary completion date: ADVICE: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (clinicaltrials.gov) - Aug 23, 2016
P1/2, N=60, Recruiting, Sponsor: Kirby Institute
Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: Aug 2016 --> Sep 2017
- Zontivity (vorapaxar) / Merck (MSD)
Enrollment open: XLPADTRACE: Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) (clinicaltrials.gov) - Jul 28, 2016
P4, N=200, Recruiting, Sponsor: North Texas Veterans Healthcare System
Trial primary completion date: Aug 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- ||| Zontivity (vorapaxar) / Merck (MSD)
Trial initiation date, Trial primary completion date: XLPADTRACE: Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) (clinicaltrials.gov) - Mar 24, 2016
P4, N=200, Not yet recruiting, Sponsor: North Texas Veterans Healthcare System
Not yet recruiting --> Recruiting Initiation date: Feb 2016 --> May 2016 | Trial primary completion date: Jan 2017 --> Jun 2017
- |||| Zontivity (vorapaxar) / Merck (MSD)
Enrollment open: OPTIMUS-5: Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus (clinicaltrials.gov) - Mar 9, 2016
P4, N=64, Recruiting, Sponsor: University of Florida
Initiation date: Feb 2016 --> May 2016 | Trial primary completion date: Jan 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- |||| Zontivity (vorapaxar) / Merck (MSD)
Enrollment open: VORA-PRATIC: Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor (clinicaltrials.gov) - Mar 9, 2016
P4, N=126, Recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Zontivity (vorapaxar) / Merck (MSD)
New P4 trial: XLPADTRACE: Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) (clinicaltrials.gov) - Jan 21, 2016
P4, N=200, Not yet recruiting, Sponsor: North Texas Veterans Healthcare System
- | Zontivity (vorapaxar) / Merck (MSD)
New P4 trial: Influence of Vorapaxar on Thrombin Generation and Coagulability (clinicaltrials.gov) - Dec 14, 2015
P4, N=100, Not yet recruiting, Sponsor: Inova Health Care Services
- ||||| Zontivity (vorapaxar) / Merck (MSD)
New P4 trial: OPTIMUS-5: Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus (clinicaltrials.gov) - Sep 14, 2015
P4, N=64, Not yet recruiting, Sponsor: University of Florida
- ||||| Zontivity (vorapaxar) / Merck (MSD)
New P4 trial: VORA-PRATIC: Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor (clinicaltrials.gov) - Sep 10, 2015
P4, N=126, Not yet recruiting, Sponsor: University of Florida
- |||| Zontivity (vorapaxar) / Merck (MSD)
Enrollment open, Trial initiation date: ADVICE: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (clinicaltrials.gov) - Sep 9, 2015
P1/2, N=60, Recruiting, Sponsor: Kirby Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015
- ||||| Zontivity (vorapaxar) / Merck (MSD)
New P2 trial: Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access (clinicaltrials.gov) - Jun 20, 2015
P2, N=128, Not yet recruiting, Sponsor: Matthew Mell
- ||||| Zontivity (vorapaxar) / Merck (MSD)
New P1/2 trial: ADVICE: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (clinicaltrials.gov) - Mar 20, 2015
P1/2, N=60, Not yet recruiting, Sponsor: Kirby Institute
- ||| Zontivity (vorapaxar) / Merck (MSD)
Trial initiation date: Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) (clinicaltrials.gov) - Jul 30, 2014
P2, N=90, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015 Initiation date: Dec 2006 --> Sep 2006
- ||| Zontivity (vorapaxar) / Merck (MSD)
Enrollment change: Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573) (clinicaltrials.gov) - Dec 5, 2013
P2, N=1030, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Dec 2006 --> Sep 2006 N=1600 --> 1030
- ||||| Zontivity (vorapaxar) / Merck (MSD)
Enrollment change: Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) (clinicaltrials.gov) - Mar 15, 2012
P3, N=261, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=1600 --> 1030 N=200 --> 261
- ||||||| Zontivity (vorapaxar) / Merck (MSD)
Trial completion: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) (clinicaltrials.gov) - Jan 18, 2012
P3, N=26449, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=200 --> 261 Active, not recruiting --> Completed